Icon
+91 94997 68112
Login Register

Malarone - (100/250 mg; Tablet)

Atovaquone and Proguanil Hydrochloride GlaxoSmithkline
100/250 mg; Tablet
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
 None
Less Than 5
Less Than 5
Indicated for: prophylaxis of Plasmodium falciparum malaria, including in areas where chloroquine resistance has been reported.
Yes
******** *** *** ***** ** **** * **** ** ** ***** ******* ******** ** *** **, **** *** *** ************ ********* ** ***************. ***** *** ******* *** ********** **** ********. ** *** ***** ** **********, ******** *** ****** ******* ** ******. **** ******** ******** ******** *** ******** *** ******* ** *** *** **********.
Malarone Patent 1 Patent 2 Patent 3
******** ******* ******* *******
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
******** *** \ *** *** **** ******* ******** ******** ** *** **, ****
  1. ****, **** : ******** ******** ***** *** **** ** ** ****** '***, '***, *** '***.
  2. ***, **** : *** ***** ******* ******* ******** ** ******** ***** ** ********.
  3. *****, **** : *** *** ******** ***** **** ********** ***** *** ***** ** ********** ******** ***** ********** ******** ***** ******* ******* ******** **** ********.
  4. *** **, **** : ******** ******** ******** **** ********.
  5. **** **, **** : ******** ******** *** *******.
  6. *** *, **** : * **** ** ** ***** *** ******* ** ******* *** *** *******

Malarone - (62.5/25mg; Tablet)

Atovaquone and Proguanil Hydrochloride GlaxoSmithkline
62.5/25mg; Tablet
Less Than $1000 mn
Less Than 5
Less Than 5
Less Than 5
 None
Less Than 5
Less Than 5
Indicated for prophylaxis of Plasmodium falciparum malaria, including in areas where chloroquine resistance has been reported
Yes
** ******* *** ******* ** **** *******. **** ******** *** ***** ***** ****, **** **** ***** *********, **** *** ***** ******** *** ******** *** ******* ** ********* ***** ***** *** ****** ** **** ********** ******.
Company FTF Status / 180 days exclusivity 30-Months stay Current Litigation Status Current Approval Status Likelihood of launch
********
  1. *** **, **** : * **** ** ** ***** *** ******* ** ******* *** *******
  2. *** **, **** : ******** *** ***** ********
  3. *** **, **** : ***** *** ***** ********
  4. *** **, **** : ***** ******** *** *******
  5. *** *, **** : ******** ******** *** *******

Download ParaIV Report

Download ParaIV Detailed Report

To get detailed report Contact Us

ParaIV Advanced Search






Please contact contact@researchdelta.com to get more details.

Headquarters

Research Delta Advisor, G4,Sani Apartment, Bank of india lane, Ellora park, Vadodara 390023

+91 94997 68112

nimish@researchdelta.com

Products & Services

Para IV GenUS Pharmalysis Consulting Valuation

Quick Links

Home About Career Media Coverage Contact
© Research Delta, All Right Reserved.